Clinical Trial Update: Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections [Phase 2]

View source ↗

Summary

An open-label Phase 2 multicenter immunogenicity and safety study evaluating the MVA-BN vaccine in children aged 2 to under 12 years, compared with adults, for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monkeypox
• Smallpox

Drugs mentioned

• MVA-BN vaccine (Modified Vaccinia Ankara-Bavarian Nordic vaccine (MVA-BN))

Snippet

Sponsor: Bavarian Nordic | Conditions: Monkeypox (Mpox) | Phase 2 | Status: ACTIVE_NOT_RECRUITING